Journal of Addictive Diseases, Год журнала: 2024, Номер unknown, С. 1 - 8

Опубликована: Дек. 28, 2024

Background: No FDA-approved medications for methamphetamine (MA) use disorder (MUD) are available. Suvorexant (SUVO), a dual orexin receptor antagonist that is FDA approved insomnia treatment, reduces MA self-administration and MA-induced reinstatement responding in preclinical studies. SUVO may also reduce by targeting substance risk factors, including insomnia, stress, cue reactivity, craving. This case series study assessed the (1) feasibility safety of administering suvorexant sample individuals with MUD; (2) preliminary effects on objective subjective measures sleep, reactivity/craving. Method: Participants (n = 3) were randomized to receive 1 week or placebo using within-subject, crossover design 1-week washout period between doses. completed self-report (sleep quality, stress), behavioral (cold pressor task), physiological (heart rate, electroencephalogram) during all three weeks. wore Fitbit monitor sleep throughout study. Results: visits tasks. One report severe drowsiness headache made; no other side associated SUVO. improved total time resulted lower resting-state alpha power, but was mixed quality. administration increased overall brain reactivity cues not specific reduced though self-reported stress demonstrated results. Conclusion: safe tolerable MUD sample. Future research benefit from investigating well-controlled larger

Язык: Английский